Natco Pharma Limited was incorporated in Hyderabad in the year 1981. Starting off as a single unit with 20 employees, Natco today has eight manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc. NATCO is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs)which makes finished dosage formulations and active pharmaceutical ingredients. The company's focus is primarily on niche therapeutic areas and complex products. It is the market leader in branded oncology medicines in India, and among the country's top three producers of hepatitis C drugs. It is well recognized for its innovation in pharmaceutical research and development (R&D). NATCO also exports its finished products through its subsidiaries in over 40 countries and collectively over 30 products across these geographies. ○ NATCOFARMA DO BRASIL (since 2011), ○ NATCO PHARMA CANADA INC. (since 2012), ○ NATCO PHARMA Asia Pte. Ltd. (since 2012) ○ NATCO Pharma Australia PTY Ltd. (since 2014).
Location: India, Telangana, Hyderabad
Employees: 1001-5000
Founded date: 1981
Investors 1
| Date | Name | Website |
| - | Multiples ... | multiplese... |
Mentions in press and media 12
| Date | Title | Description |
| 08.05.2024 | Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings | - |
| 04.05.2024 | Productivity loss due to oral cancer in India in 2022 at $5.6 bn: Study | - |
| 01.05.2024 | Mizoram sees alarming surge in TB deaths, 108 succumb to disease in 2023 | - |
| 23.04.2024 | Natco Pharma gets EIR from USFDA on pharmacovigilance requirements | Natco Pharma has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA). In November last year, Hyderabad-based Natco informed the successful completion of the United States Food and Drug Adminis... |
| 21.04.2024 | USFDA pulls up Natco Pharma for several violations at Telangana plant | - |
| 09.04.2024 | Maruti Suzuki Expands Manesar Plant's Capacity, Air India Addresses Uniform Issues, Indian Tech Startups See Decline in Layoffs | Maruti Suzuki India has boosted the production capacity of its Manesar facility by 100,000 units per annum, aiming to double its capacity to 4 million vehicles per annum in the next 7-8 years. The expansion includes a new vehicle assembly l... |
| 09.04.2024 | Maruti Suzuki expands Manesar plant's capacity by 100K units per annum | Maruti Suzuki India on Tuesday said it has expanded the production capacity of its Manesar facility by one lakh units per annum. The auto major has added a vehicle assembly line to the existing Plant-A of the three manufacturing plants func... |
| 09.04.2024 | Natco Pharma receives warning letter from USFDA for Telangana plant | Natco Pharma on Tuesday said it has received a warning letter from the US health regulator for its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) had issued eight observations under Form 483 after inspectin... |
| 09.04.2024 | A-I takes cognizance of fabric issues flagged in new cabin crew uniforms | Air India has received feedback on the new cabin crew uniforms, including about fabric issues, and will soon start their production for all the cabin crew after taking into consideration the inputs, according to people in the know. In Decem... |
| 09.04.2024 | Merck India appoints Dhananjay Singh as MD of its Life Science unit | Merck, a leading science and technology company, on Tuesday announced the appointment of Dhananjay Singh as the managing director of Merck Life Science in India. Effective April 1, 2024, Singh has taken over from Sreenath N S, who is retiri... |
Show more